BARCELONA, Spain, Jan. 4, 2022 /PRNewswire/ -- Grifols (MCE: GRF,
MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of
world's top producers of plasma-derived medicines, today announced
the acquisition of its first donation center in Canada as part of the company's commitment to
increase the availability of lifesaving plasma medicines in the
country.
In a share-purchase agreement, Grifols Canada Therapeutics Inc
has acquired Prometic Plasma Resources Inc's (PPR) donation center
in Winnipeg from Kedrion for
USD 4 million in cash.
With the center, Grifols furthers its growth strategy in
Canada, where it already has a
plasma fractionation plant with an annual capacity of 1.5 million
liters and two purification facilities that it purchased in 2020.
The production plants are currently being developed and are
expected to be operational in 2023.
Grifols is already familiar with PPR's high quality and safety
standards through an existing relationship in which the center
provides Grifols with anti-Rho(D) plasma.
"We are excited to establish the first Grifols donor center in
Canada," said Víctor Grifols Deu,
co-CEO of Grifols, which has a network of more than 350 centers,
the world's largest. "We are clear in our commitment to helping
countries globally ensure the availability of lifesaving plasma
medicines for their citizens."
The company has gained deep knowledge of Canada's plasma market and healthcare system
over the more than 30 years it has fractionated Canadian plasma in
its U.S. production plants. This contract manufacturing services
arrangement enables Grifols to provide plasma-derived medicines
that enhance the lives of thousands of Canadian patients.
Grifols will file notifications of the acquisition with the
applicable Canadian authorities, including Health Canada and the
government's foreign-investment authorities.
Grifols retained Osborne Clarke, S.L.P. as legal advisor.
About Grifols
Grifols is a global healthcare company
founded in Barcelona in 1909
committed to improving the health and well-being of people around
the world. Its four divisions – Bioscience, Diagnostic, Hospital
and Bio Supplies – develop, produce and market innovative solutions
and services that are sold in more than 100 countries.
Pioneers in the plasma industry, Grifols operates a growing
network of donation centers worldwide. It transforms collected
plasma into essential medicines to treat chronic, rare and, at
times, life-threatening conditions. As a recognized leader in
transfusion medicine, Grifols also offers a comprehensive portfolio
of solutions designed to enhance safety from donation to
transfusion. In addition, the company supplies tools, information
and services that enable hospitals, pharmacies and healthcare
professionals to efficiently deliver expert medical care.
Grifols, with nearly 24,000 employees in more than 30 countries
and regions, is committed to a sustainable business model that sets
the standard for continuous innovation, quality, safety and ethical
leadership.
In 2020, Grifols' economic impact in its core countries of
operation was EUR 7.5 billion. The
company also generated 140,000 jobs, including indirect and
induced.
The company's class A shares are listed on the Spanish Stock
Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols
non-voting class B shares are listed on the Mercado Continuo
(MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).
For more information, please visit www.grifols.com
LEGAL DISCLAIMER
The facts and figures
contained in this report that do not refer to historical data are
"future projections and assumptions". Words and expressions such as
"believe", "hope", "anticipate", "predict", "expect", "intend",
"should", "will seek to achieve", "it is estimated", "future" and
similar expressions, insofar as they relate to the Grifols group,
are used to identify future projections and assumptions. These
expressions reflect the assumptions, hypotheses, expectations and
predictions of the management team at the time of writing this
report, and these are subject to a number of factors that mean that
the actual results may be materially different. The future results
of the Grifols group could be affected by events relating to its
own activities, such as a shortage of supplies of raw materials for
the manufacture of its products, the appearance of competitor
products on the market, or changes to the regulatory framework of
the markets in which it operates, among others. At the date of
compiling this report, the Grifols group has adopted the necessary
measures to mitigate the potential impact of these events. Grifols,
S.A. does not accept any obligation to publicly report, revise or
update future projections or assumptions to adapt them to events or
circumstances subsequent to the date of writing this report, except
where expressly required by the applicable legislation. This
document does not constitute an offer or invitation to buy or
subscribe shares in accordance with the provisions of the following
Spanish legislation: Royal Legislative Decree 4/2015, of 23
October, approving recast text of Securities Market Law;
Royal Decree Law 5/2005, of 11 March
and/or Royal Decree 1310/2005, of 4
November, and any regulations developing this legislation. In
addition, this document does not constitute an offer of purchase,
sale or exchange, or a request for an offer of purchase, sale or
exchange of securities, or a request for any vote or approval in
any other jurisdiction. The information included in this document
has not been verified nor reviewed by the external auditors of the
Grifols group
View original content to download
multimedia:https://www.prnewswire.com/news-releases/grifols-acquires-its-first-plasma-donation-center-in-canada-301453787.html
SOURCE Grifols